TMDX Stock Overview
A commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
TransMedics Group, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$156.10 |
| 52 Week High | US$171.98 |
| 52 Week Low | US$36.42 |
| Beta | 1.98 |
| 11 Month Change | 2.46% |
| 3 Month Change | 22.70% |
| 1 Year Change | 135.41% |
| 33 Year Change | 420.33% |
| 5 Year Change | 650.12% |
| Change since IPO | 598.12% |
Recent News & Updates
Analysts Just Made A Meaningful Upgrade To Their TransMedics Group, Inc. (NASDAQ:TMDX) Forecasts
Aug 06
TransMedics Group: Providing Long-Term Detailed Forecast And Upgrading To Buy
Aug 04TransMedics Group, Inc. Just Recorded A 66% EPS Beat: Here's What Analysts Are Forecasting Next
Aug 02TransMedics Group Stock: Too Far, Too Fast
Jul 08Recent updates
Analysts Just Made A Meaningful Upgrade To Their TransMedics Group, Inc. (NASDAQ:TMDX) Forecasts
Aug 06TransMedics Group: Providing Long-Term Detailed Forecast And Upgrading To Buy
Aug 04TransMedics Group, Inc. Just Recorded A 66% EPS Beat: Here's What Analysts Are Forecasting Next
Aug 02TransMedics Group Stock: Too Far, Too Fast
Jul 08TransMedics: NOP, Logistics And Transport Are Key Growth Drivers But Stock Is Pricey
Jun 17TransMedics Group (NASDAQ:TMDX) Might Have The Makings Of A Multi-Bagger
Jun 10TransMedics: Transportation Supporting Growth
May 21TransMedics Group: Looking At The Road Ahead After An Exceptional Q1 (Rating Downgrade)
May 06TransMedics Group, Inc. (NASDAQ:TMDX) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Apr 24TransMedics Group: Founder Led Company With Solid Potential
Apr 19Is TransMedics Group (NASDAQ:TMDX) Using Too Much Debt?
Apr 11TransMedics Group: Emerging Medical Device Market Leader With A Long Growth Runway
Mar 19TransMedics Group: Huge Opportunity In Organ Transplants
Mar 12TransMedics: A Very Expensive Growth Stock
Feb 07With TransMedics Group, Inc. (NASDAQ:TMDX) It Looks Like You'll Get What You Pay For
Jan 23Calculating The Fair Value Of TransMedics Group, Inc. (NASDAQ:TMDX)
Jan 02Does TransMedics Group (NASDAQ:TMDX) Have A Healthy Balance Sheet?
Nov 05This Just In: Analysts Are Boosting Their TransMedics Group, Inc. (NASDAQ:TMDX) Outlook for This Year
Aug 06TransMedics Group (NASDAQ:TMDX) Has Debt But No Earnings; Should You Worry?
Aug 02TransMedics Group, Inc. (NASDAQ:TMDX) Not Lagging Industry On Growth Or Pricing
Jun 29Brokers Are Upgrading Their Views On TransMedics Group, Inc. (NASDAQ:TMDX) With These New Forecasts
May 06Is TransMedics Group (NASDAQ:TMDX) Using Too Much Debt?
Apr 27Estimating The Intrinsic Value Of TransMedics Group, Inc. (NASDAQ:TMDX)
Apr 09Is TransMedics Group (NASDAQ:TMDX) A Risky Investment?
Jan 16TransMedics: Game Changer Technology Will Boost Revenue Growth
Oct 20Shareholder Returns
| TMDX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 12.8% | 0.2% | -4.2% |
| 1Y | 135.4% | 2.7% | 14.1% |
Return vs Industry: TMDX exceeded the US Medical Equipment industry which returned -0.7% over the past year.
Return vs Market: TMDX exceeded the US Market which returned 12.4% over the past year.
Price Volatility
| TMDX volatility | |
|---|---|
| TMDX Average Weekly Movement | 5.8% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 14.4% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: TMDX's share price has been volatile over the past 3 months.
Volatility Over Time: TMDX's weekly volatility has decreased from 11% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 584 | Waleed Hassanein | www.transmedics.com |
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers.
TransMedics Group, Inc. Fundamentals Summary
| TMDX fundamental statistics | |
|---|---|
| Market cap | US$4.95b |
| Earnings (TTM) | US$3.00m |
| Revenue (TTM) | US$358.76m |
1,736x
P/E Ratio14.5x
P/S RatioIs TMDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TMDX income statement (TTM) | |
|---|---|
| Revenue | US$358.76m |
| Cost of Revenue | US$140.95m |
| Gross Profit | US$217.81m |
| Other Expenses | US$214.81m |
| Earnings | US$3.00m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.09 |
| Gross Margin | 60.71% |
| Net Profit Margin | 0.84% |
| Debt/Equity Ratio | 267.4% |
How did TMDX perform over the long term?
See historical performance and comparison